Abstracts Archive - Page 523 of 1683 - ATC Abstracts

2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
K. Soliman¹, H. Ali², T. Fulop¹, A. Osman³, A. Halawa⁴
¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine, Royal Stoke, Royal Stoke, United Kingdom, ³Medicine, Cairo University, Cairo, Egypt, ⁴Medicine, University of Liverpool, Liverpool, United Kingdom
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
2020 American Transplant Congress
Potential Cost-Savings Associated with ANG-3777 for the Treatment of Delayed Graft Function in Kidney Transplantation
M. Cooper¹, T. Mayne², T. Kauf³, M. Gargano³, K. Freemyer³
¹Medstar Georgetown Transplant Institute, Washington, DC, ²Angion Biomedica Corp, San Francisco, CA, ³Genesis Research, Hoboken, NJ
*Purpose: We created a medical cost offset model based upon the results of a Phase 2, double-blind, randomized controlled trial of ANG-3777, a hepatocyte growth…
2020 American Transplant Congress
The Use of Interviews to Explore the Public Attitudes on the Use of Imminent Death Donation
P. Moolchandani¹, L. Washburn¹, M. Goss², S. Parsons³, R. Brown³, E. Ranova³, R. Ackah¹, K. Myer⁴, R. Wood⁴, A. Rana¹, J. Goss¹, T. Galván¹
¹Division of Abdominal Transplantation, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, ²University of Houston College of Medicine, Houston, TX, ³Rice University, Houston, TX, ⁴LifeGift, Houston, TX
*Purpose: Imminent death donation (IDD) describes non-fatal recovery of a living donor organ (a single kidney or partial liver) prior to a planned withdrawal of…
2020 American Transplant Congress
Implicit Bias in Recipient Selection
Y. Sweidan¹, C. Mayuga¹, B. Daly¹, K. Chavin², T. Srinivas¹, A. Padiyar¹
¹Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: The decision to place or exclude a candidate from the waitlist is not exclusively based on medical criteria. Scant literature exists regarding the intergroup…
2020 American Transplant Congress
The 1-Year Incremental Costs of Delayed Graft Function (DGF) in Commercially Insured Kidney Transplant Patients Under 65
T. Mayne¹, F. Corvino², A. Dillon², W. Wang², S. Mohan³
¹Angion Biomedica Corp, San Francisco, CA, ²Genesis Research, Hoboken, NJ, ³Columbia University Medical Center, New York, NY
*Purpose: Strong evidence exists that DGF is associated with poor patient outcomes. The long-term impact of DGF on health resource use and cost, however, is…
2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
C. Larsen¹, F. Vincenti², T. Kou³, C. Shadur⁴, B. Bresnahan⁵, S. Jordan⁶, E. S. Woodle⁷, N. Goes⁸, J. Vella⁹, D. Wojciechowski¹⁰, M. Polinsky³, A. Gomez-Caminero³
¹Emory University Transplant Center, Atlanta, GA, ²UCSF Transplant Center, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Iowa Kidney Physicians, Des Moines, IA, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Cincinnati, Cincinnati, OH, ⁸Kaiser Permanente, San Francisco, CA, ⁹Maine Nephrology Associates, PA, Portland, ME, ¹⁰University Hospital Kidney and Liver Transplant Clinic, Dallas, TX
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
T. Schiff, R. Bodin, I. Lee, K. Okumura, D. C. Wolf, A. Dhand, A. L. Gass, D. Spielvogel, G. Veillette, S. Nishida, D. Glicklich, K. Wolfe, T. Diflo, H. Sogawa
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…
2020 American Transplant Congress
The Importance of Annual Medicare Part D Plan Evaluation
L. Potter¹, E. Garrity²
¹Department of Pharmacy, University of Chicago Medicine, Chicago, IL, ²Transplant Institute, University of Chicago Medicine, Chicago, IL
*Purpose: The Medicare open enrollment period is from Oct 15 to Dec 7, annually. The purpose of this project was to objectively measure the benefit…
2020 American Transplant Congress
Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain
C. Rubio¹, C. Jiménez², M. Crespo³, J. Portolés⁴, D. Rubio¹, T. Diez⁵, I. Portero⁵
¹Health Value, Madrid, Spain, ²La Paz Hospital, Madrid, Spain, ³Consorci Mar Parc de Salut, Barcelona, Spain, ⁴Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ⁵Biohope Scientific Solutions for Human Health SL, Madrid, Spain
*Purpose: Immunobiogram (IMBG) is a new IVD bioassay developed by Biohope SL with the aim to support clinicians in the personalized adjustment of immunosuppressive therapy…
2020 American Transplant Congress
Accommodating Increasing Volumes without Knocking Down Walls: Update on an Infusion Center’s Growth
J. C. Estrada
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: An increase in transplants performed at the medical center in comparison to the limited availability of outpatient infusion chairs and home infusion companies compelled…